Form 4: Relay Therapeutics Director Receives Stock Option Grant

Director Claire Mazumdar was granted 32,947 stock options in Relay Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Claire Mazumdar received a grant of 32,947 stock options on June 9, 2026.
• The options have an exercise price of $14.09 per share.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the options relative to the exercise price.

Future Outlook

The options vest in full by June 2027 or the next annual meeting, whichever comes first, indicating a standard retention and incentive structure.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, particularly for companies like Relay Therapeutics focused on long-term drug discovery pipelines.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap clinical-stage biopharmaceutical companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 9, 2027, or the next annual stockholders meeting.

Key Dates

Keywords

Relay Therapeutics, RLAY, Insider Trading, Stock Options, Director Compensation, SEC Form 4